CASMED Engages Gamida to Distribute FORE-SIGHT(R) Oximeters in France

CAS Medical Systems Logo

BRANFORD, Conn., April 16, 2014 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, today announced that it has signed an agreement with Gamida to serve as the exclusive distributor of the Company's FORE-SIGHT® Cerebral Oximeters in France.

Gamida has been an independent distributor of high-quality medical products in France for more than 50 years. It has 26 sales representatives and four clinical specialists supporting more than 2,300 customers in France, with a primary focus on anesthesia, cardiac and vascular surgery and critical care.

"Establishing high-quality distribution in the world's fifth largest medical products market represents another key milestone for our Company," said Thomas Patton, CASMED's President and CEO. "With Gamida's expansive reach and intimate knowledge of this untapped market for FORE-SIGHT oximeters, we expect this relationship will add another source of growth for FORE-SIGHT revenues."

"We look forward to working closely with Gamida to establish the FORE-SIGHT ELITE Oximeter as the market leader in France by empowering clinicians to provide better care to their patients," said Karen Coleman, CASMED's newly appointed Executive Vice President of International Sales. "With this latest distribution agreement, our FORE-SIGHT line of products is now available in 18 countries worldwide including the U.S., China, Germany and France."

"The FORE-SIGHT product will be a natural complement to our current physician call point," said Carole Dautremant, Executive Vice President of Gamida. "The occurrence of oxygen desaturation during and after surgery is becoming a real concern, and with a best-in-class monitoring system we look forward to educating the marketplace about the risks while simultaneously establishing FORE-SIGHT as the solution of choice."

About CASMED® – Monitoring What's Vital

CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximetry technology provides highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care. For further information regarding CASMED, visit the Company's website at

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company's Form 10-K for the year ended December 31, 2013, and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Company Contact
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
(203) 315-6303

Investor Contact
Bruce Voss (
(310) 691-7100

Source:CAS Medical Systems, Inc.